Hi there!
We track 70,000+ AI startups and surface hidden job opportunities that never appear on LinkedIn. Tell us what you're looking for, our AI agent does the searching. It's free and you sign up using Google. Go explore!
A2A Pharmaceuticals
A2A Pharmaceuticals is a clinical-stage oncology company focused on leveraging proprietary computational systems, including AI, to accelerate the development of novel drug alternatives for…
A2A Pharmaceuticals
A2A Pharmaceuticals is a clinical-stage oncology company focused on leveraging proprietary computational systems, including AI, to accelerate the development of novel drug alternatives for…
TL;DR
Stage: Clinical-stage (Phase 1 for AO-252)
Core tech: SCULPT AI-driven small-molecule design platform
Lead asset: AO-252 (TACC3 PPI inhibitor)
Founded / HQ: 2016; New York City
Reported funding: $5M raised; investors include SOSV/IndieBio
Company Overview
Problem Domain
Oncology (ovarian, triple-negative, endometrial cancers; expanding to prostate, gastric, sarcoma, brain metastasis) and antibiotic-resistant bacterial infections.
Founded
2016
Industry
Biotechnology
Tech Stack
Funding Track Record
Most recently reported funding event per public profiles
Investor Signal
“Participation by accelerator/venture investor SOSV (IndieBio) reported”